Halozyme Therapeutics
(NASDAQ:HALO)
$38.64
0.83[2.20%]
At close: Apr 19
$38.64
0[0.00%]
After Hours: 4:20PM EDT
OverviewNewsEarningsGuidanceDividendsAnalyst RatingsInsider TradesShort Interest
62.5%
Overview Rating
Good
Technicals Analysis
100
0100
Financials Analysis
40
0100

Halozyme Therapeutics Stock (NASDAQ:HALO), Quotes and News Summary

Halozyme Therapeutics Stock (NASDAQ: HALO) stock price, news, charts, stock research, profile.

Open$37.730
Close$38.640
Volume / Avg.1.259M / 1.139M
Day Range37.730 - 38.690
52 Wk Range29.850 - 45.000
Market Cap$4.909B
P/E Ratio18.005
Dividend Yield-
ExchangeNASDAQ
RSI
44
Short Interest
8.4%
Days to Cover10.21

Recent News

Why Biophytis Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket
Shares of Biophytis S.A. (NASDAQ: BPTS) rose sharply in today’s pre-market trading after reporting FY23 results.
Avi Kapoor
Sponsored
Gates Ventures, Mayo Clinic Back Tiny Robot Created By $400M Apple Face ID Inventors To Treat Brain Disease
Michael Shpigelmacher, Founder and CEO of Bionaut Labs, with the company’s micro-robot designed to swim through the central nervous system into the brain to treat disease now on trial in the U.S.
Bristol Myers' Lead Cancer Drug Opdivo Formulated As Under Skin Injection At Par With Intravenous Infusion In Kidney Cancer Patients
Results from Bristol Myers Squibb's Phase 3 CheckMate -67T trial on subcutaneous Opdivo (nivolumab) for advanced clear cell renal cell carcinoma. Noninferiority compared to IV Opdivo.
Vandana Singh
40%

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change
Analyst Trend
1
Dec 23
3
1
Jan
2
Feb
2
Apr
Buy
Hold
Sell
Strong Sell
Analyst Rating
12345
4.1
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell
About Halozyme Therapeutics Inc.
Sector
Health Care
Industry
Biotechnology
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel...
Show More

Compare

EPS better than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
HALO
IMVT

FAQ

Q

How do I buy Halozyme Therapeutics (HALO) stock?

A

You can purchase shares of Halozyme Therapeutics (NASDAQ: HALO) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Halozyme Therapeutics's (HALO) competitors?

A

Other companies in Halozyme Therapeutics’s space includes: Immunovant (NASDAQ:IMVT), Legend Biotech (NASDAQ:LEGN), Ultragenyx Pharmaceutical (NASDAQ:RARE), Ionis Pharmaceuticals (NASDAQ:IONS) and Cerevel Therapeutics Hldg (NASDAQ:CERE).

Q

What is the target price for Halozyme Therapeutics (HALO) stock?

A

The latest price target for Halozyme Therapeutics (NASDAQ: HALO) was reported by HC Wainwright & Co. on Wednesday, April 17, 2024. The analyst firm set a price target for 50.00 expecting HALO to rise to within 12 months (a possible 29.40% upside). 23 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Halozyme Therapeutics (HALO)?

A

The stock price for Halozyme Therapeutics (NASDAQ: HALO) is $38.64 last updated April 19, 2024 at 4:20 PM EDT.

Q

Does Halozyme Therapeutics (HALO) pay a dividend?

A

There are no upcoming dividends for Halozyme Therapeutics.

Q

When is Halozyme Therapeutics (NASDAQ:HALO) reporting earnings?

A

Halozyme Therapeutics’s Q1 earnings are confirmed for Tuesday, May 7, 2024.

Q

Is Halozyme Therapeutics (HALO) going to split?

A

There is no upcoming split for Halozyme Therapeutics.

Q

What sector and industry does Halozyme Therapeutics (HALO) operate in?

A

Halozyme Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch